All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
What are the best strategies for long-term management of hematotoxicity associated with CAR-T?
Featured:
Marion SubkleweDuring the European School of Haematology (ESH) How I manage CAR-T Therapies and Bispecific Antibodies for my Patients conference, the Lymphoma Hub spoke to Marion Subklewe, LMU, Munich, DE. We asked, What are the best strategies for long-term management of hematotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy?
What are the best strategies for long-term management of hematotoxicity associated with CAR-T?
Subklewe begins by outlining findings on the high number of patients presenting with neutropenia and cytopenia post CAR-T. She goes on to identify three clinical phenotypes of neutropenia and their implications. Subklewe explains a scoring system predicting hematotoxicity, which can support risk stratification. She discusses prophylaxis regimens including aciclovir, cotrimoxazole, G-CSF immunoglobulin, and antifungals. Finally, she highlights the importance of monitoring patients after CAR-T.